CO5180567A1 - Sal polimor - Google Patents
Sal polimorInfo
- Publication number
- CO5180567A1 CO5180567A1 CO00059853A CO00059853A CO5180567A1 CO 5180567 A1 CO5180567 A1 CO 5180567A1 CO 00059853 A CO00059853 A CO 00059853A CO 00059853 A CO00059853 A CO 00059853A CO 5180567 A1 CO5180567 A1 CO 5180567A1
- Authority
- CO
- Colombia
- Prior art keywords
- polymor
- salt
- alpha1
- mfi
- migraine
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 102000035038 5-HT1 receptors Human genes 0.000 abstract 1
- 108091005478 5-HT1 receptors Proteins 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El presente invento trata de una forma polimórfica cristalina de un compuesto de fórmula (I)<EMI FILE="00059853_1" ID="1" IMF=JPEG >caracterizada por un diagrama de difracción de rayos X en polvo, obtenido al utilizar la radiación K-alfa1 del cobre (? = 0,15046 nm), que presenta picos principales a 9,28, 10,38, 11,37, 12,40, 16,84, 17,46, 17,53, 17,78, 17,98, 19,48, 20,70, 21,29, 21,45, 22,21, 22,64, 23,08, 25,20, y 25,79.El invento se refiere también a procedimientos para la preparación de dicha forma, a composiciones farmacéuticas que contienen la misma y a su uso en medicina, particularmente en el tratamiento de estados para los que se prescribe un agonista de receptores 5-HT1, tales como, por ejemplo, la migraña.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922963.5A GB9922963D0 (en) | 1999-09-28 | 1999-09-28 | Polymorphic salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5180567A1 true CO5180567A1 (es) | 2002-07-30 |
Family
ID=10861767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00059853A CO5180567A1 (es) | 1999-09-28 | 2000-08-10 | Sal polimor |
Country Status (50)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214711B2 (en) * | 1998-12-23 | 2007-05-08 | Neurotherapeutics Pharma Llc | Method of treating migraine headache without aura |
| US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
| GB0312478D0 (en) * | 2003-05-30 | 2003-07-09 | Pfizer Ltd | Improved process |
| US7132549B2 (en) | 2003-05-30 | 2006-11-07 | Pfizer Inc. | Process |
| AU2005311714B2 (en) * | 2004-12-03 | 2010-09-30 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
| JP2009511629A (ja) * | 2005-10-17 | 2009-03-19 | ニューロセラピューティクス ファーマ， インコーポレイテッド | 中枢神経系疾患の調節に有用な利尿薬様化合物類似体 |
| KR100814109B1 (ko) * | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
| TWI394753B (zh) | 2006-03-17 | 2013-05-01 | Otsuka Pharma Co Ltd | 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體 |
| WO2010116386A2 (en) * | 2009-04-08 | 2010-10-14 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of eletriptan hydrobromide and process for the preparation thereof |
| ES2898348T3 (es) | 2009-10-26 | 2022-03-07 | Merck Sharp & Dohme | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5578612A (en) | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| US5559246A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| KR0179053B1 (ko) * | 1990-10-15 | 1999-03-20 | 알렌 제이.스피겔 | 인돌 유도체 |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| US5998462A (en) * | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| UY25078A1 (es) * | 1997-07-03 | 2000-12-29 | Pfizer | Composiciones farmacéuticas que contienen eletriptan hemisulfato estabilizadas con cafeína |
-
1999
- 1999-09-28 GB GBGB9922963.5A patent/GB9922963D0/en not_active Ceased
-
2000
- 2000-07-25 TW TW089114850A patent/TWI265926B/zh not_active IP Right Cessation
- 2000-07-28 PA PA20008498901A patent/PA8498901A1/es unknown
- 2000-08-10 CO CO00059853A patent/CO5180567A1/es not_active Application Discontinuation
- 2000-09-14 SK SK398-2002A patent/SK3982002A3/sk unknown
- 2000-09-14 EE EEP200200171A patent/EE200200171A/xx unknown
- 2000-09-14 AU AU67213/00A patent/AU779580B2/en not_active Ceased
- 2000-09-14 EA EA200200302A patent/EA004510B1/ru not_active IP Right Cessation
- 2000-09-14 DK DK00954864T patent/DK1233960T3/da active
- 2000-09-14 ES ES00954864T patent/ES2200911T3/es not_active Expired - Lifetime
- 2000-09-14 EP EP00954864A patent/EP1233960B1/en not_active Expired - Lifetime
- 2000-09-14 PL PL00354960A patent/PL354960A1/xx not_active IP Right Cessation
- 2000-09-14 AP APAP/P/2002/002457A patent/AP2004A/en active
- 2000-09-14 TR TR2002/00804T patent/TR200200804T2/xx unknown
- 2000-09-14 UA UA2002032432A patent/UA72272C2/uk unknown
- 2000-09-14 IL IL14715400A patent/IL147154A/xx not_active IP Right Cessation
- 2000-09-14 MX MXPA02003311A patent/MXPA02003311A/es active IP Right Grant
- 2000-09-14 CZ CZ2002971A patent/CZ2002971A3/cs unknown
- 2000-09-14 OA OA1200200077A patent/OA12024A/en unknown
- 2000-09-14 DE DE60004262T patent/DE60004262T2/de not_active Expired - Lifetime
- 2000-09-14 YU YU2602A patent/YU2602A/sh unknown
- 2000-09-14 HU HU0202821A patent/HUP0202821A3/hu unknown
- 2000-09-14 CN CNB00810798XA patent/CN1155594C/zh not_active Expired - Fee Related
- 2000-09-14 KR KR10-2002-7003963A patent/KR100479897B1/ko not_active Expired - Fee Related
- 2000-09-14 AT AT00954864T patent/ATE246185T1/de not_active IP Right Cessation
- 2000-09-14 DZ DZ003254A patent/DZ3254A1/fr active
- 2000-09-14 CA CA002379572A patent/CA2379572C/en not_active Expired - Fee Related
- 2000-09-14 HR HR20020270A patent/HRP20020270B1/xx not_active IP Right Cessation
- 2000-09-14 HK HK03100144.2A patent/HK1048628B/zh not_active IP Right Cessation
- 2000-09-14 BR BR0014272-7A patent/BR0014272A/pt not_active Application Discontinuation
- 2000-09-14 PT PT00954864T patent/PT1233960E/pt unknown
- 2000-09-14 JP JP2001526529A patent/JP3795395B2/ja not_active Expired - Fee Related
- 2000-09-14 NZ NZ516093A patent/NZ516093A/xx unknown
- 2000-09-14 GE GE4699A patent/GEP20043365B/en unknown
- 2000-09-14 SI SI200030165T patent/SI1233960T1/xx unknown
- 2000-09-14 WO PCT/IB2000/001305 patent/WO2001023377A2/en not_active Ceased
- 2000-09-19 US US09/664,946 patent/US6369094B1/en not_active Expired - Fee Related
- 2000-09-25 EG EG20001216A patent/EG24143A/xx active
- 2000-09-26 AR ARP000105032A patent/AR025779A1/es active IP Right Grant
- 2000-09-26 GT GT200000159A patent/GT200000159A/es unknown
- 2000-09-26 PE PE2000001010A patent/PE20010662A1/es not_active Application Discontinuation
- 2000-09-26 MY MYPI20004476A patent/MY121170A/en unknown
- 2000-09-27 TN TNTNSN00187A patent/TNSN00187A1/fr unknown
-
2001
- 2001-12-10 CU CU20010293A patent/CU23200A3/es not_active IP Right Cessation
- 2001-12-19 BG BG106240A patent/BG65161B1/bg unknown
-
2002
- 2002-01-08 IS IS6223A patent/IS2162B/is unknown
- 2002-01-24 CR CR6561A patent/CR6561A/es not_active Application Discontinuation
- 2002-03-15 MA MA26556A patent/MA26821A1/fr unknown
- 2002-03-26 NO NO20021525A patent/NO321936B1/no not_active IP Right Cessation
- 2002-03-26 ZA ZA200202406A patent/ZA200202406B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5180567A1 (es) | Sal polimor | |
| ECSP044975A (es) | Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, metodos de preparación y composiciones que los contienen | |
| CO5390079A1 (es) | Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina | |
| RU97104885A (ru) | Соли производного индола против мигрени | |
| IL110494A0 (en) | Perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them | |
| AR034124A1 (es) | Forma cristalina alfa de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| RU2008149242A (ru) | Малеатный сокристалл azd1152 | |
| TW200529850A (en) | Methods of preparing aripiprazole crystalline forms | |
| HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
| HU229358B1 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| CA2410311A1 (en) | Barbituric acid analogs as therapeutic agents | |
| RU2006142521A (ru) | Средство для улучшения когнитивных функций и памяти на основе гидрированных пиридо(4,3-b)индолов (варианты), фармакологическое средство на его основе и способ его применения | |
| JO2793B1 (en) | The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains | |
| CA2415442A1 (fr) | Nouvelle forme cristalline .beta. du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
| US20140171646A1 (en) | Amorphous forms of palonosetron hydrochloride | |
| TW200736198A (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| MA30276B1 (fr) | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| MA28449B1 (fr) | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
| RU2003118411A (ru) | Кристаллические производные 1-метилкарбапенема | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| RU2000125889A (ru) | Замещенные бисиндолималеимиды, предназначенные для ингибирования пролиферации клеток | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| CA2437994A1 (en) | Crystalline forms of pyrimidine nucleoside derivative | |
| ECSP003681A (es) | Sal polimorfica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |